

## Guidelines on Aortic Disease 2014 (TF05) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Aboyans Victor	None declared (2011-2012-2013) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Pfizer : Anticoagulation (2014) - Bayer AG : Anticoagulation (2014) - Merck Sharp & Dohme : Dyslipidemia (2014) - Servier : Heart Failure (2014)
Boileau Catherine	None declared (2011-2012) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Amgen : PCSK9 (2013-2014) - Sanofi Aventis : PCSK9 (2013-2014)
Bossone Eduardo	None declared (2011-2012-2013-2014)
Di Bartolomeo Roberto	None declared (2011-2012-2013-2014)
Eggebrecht Holger	None declared (2011-2012-2013-2014)
Erbel Raimund	None declared (2014) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Biotronik : Balloons, Stents (2011-2012) - Volcano : IVUS (2011-2012) - Astra Zeneca : Rosuvastatin (2011-2012) - Evasc : Stents (2011-2012) - Biotronik : Coronary stents (2013) D - Research funding (departmental or institutional). - Siemens Healthcare : Catheterization (2011)
Evangelista Masip Artur	None declared (2011-2013-2014) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bolton Medical : Speaker fee (2012)

## Guidelines on Aortic Disease 2014 (TF05) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Falk Volkmar	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Valves (2011-2012-2013-2014)</li> <li>- Medtronic : valves (2011-2012-2013-2014)</li> <li>- Valtech : Valves (2011-2012-2013-2014)</li> <li>- Boston Scientific : Valves (2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Philips : Imaging (2011-2012-2013-2014)</li> </ul>
Frank Herbert	None declared (2011-2012-2013-2014)
Gaemperli Oliver	<p>None declared (2013)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Antiplatelet therapy (2011)</li> <li>- Guerbet : Contrast agent for CT (2011)</li> <li>- GE Healthcare : Noninvasive Cardiac Imaging (SPECT, PET, CT) (2011)</li> <li>- Abbott Vascular : MitraClip (2011-2012-2014)</li> <li>- Astra Zeneca : Antiplatelet Agents, Speakers fees (2012)</li> <li>- General Electric : CT (2012)</li> <li>- Guerbet : Hybrid Imaging (2012)</li> <li>- Abbott Vascular : Absorb BVS (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : MitraClip (2011-2012)</li> </ul>
Grabenwoeger Martin	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Jotec, Hechingen, Germany : Hybrid Endovascular Prosthesis (Frozen Elephant Trunk) (2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Edwards Lifesciences : Heart Valve (2011-2012-2013-2014)</li> <li>- Medtronic : Heart Valve (2011-2012-2013-2014)</li> <li>- St Jude Medical : Heart Valve (2011-2012-2013-2014)</li> </ul>

## Guidelines on Aortic Disease 2014 (TF05) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Haverich Axel	D - Research funding (departmental or institutional). - Deutsche Forschungsgemeinschaft : REBIRTH (2011-2012-2013-2014)
Iung Bernard	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : None (educational program) (2011) - Servier : benfluorex (2011-2012) - Bayer : rivaroxaban (2011-2012-2013) - Boehringer-Ingelheim : dabigatran (2011-2012-2013-2014) - Edwards Lifesciences : heart valve prosthesis (2011-2012-2013-2014) - Abbott : Mitraclip (2011-2012-2013-2014)
Manolis Athanasios John	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Abbott : Hypertension, (2011-2012-2013-2014) - Menarini : hypertension, heart failure (2011-2012-2013-2014) - Servier : hypertension (2014) - Recordati International : hypertension (2014)  D - Research funding (departmental or institutional). - Bayer : AF (2011-2012-2013-2014) - Boehringer-Ingelheim : AF (2011-2012-2013-2014) - GlaxoSmithKline : Coronary Heart Disease (2011-2012-2013-2014) - Servier : Heart Failure (2011-2012-2013-2014)
Meijboom Folkert	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion : Pulmonary hypertension (2011-2012-2013)  D - Research funding (departmental or institutional). - Actelion : Pulmonary hypertension (2011-2012-2013-2014)
Nienaber Christopher	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boston Scientific : stent (2011-2012) - Medtronic : Valiant and Endurant Stentgraft (2013-2014)

## Guidelines on Aortic Disease 2014 (TF05) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Nienaber Christopher	D - Research funding (departmental or institutional). - Medtronic Foundation : Stentgraft / INSTEAD-XL study (2013)
Roffi Marco	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Daiichi Sankyo : antiplatelet therapy (2011-2012-2013) - Lilly : antiplatelet therapy (2011-2012-2013) - Astra Zeneca : antiplatelet therapy (2011-2012-2013)  D - Research funding (departmental or institutional). - Cordis : devices (2011) - Biosensors : devices (2011-2012-2013-2014) - Boston Scientific : devices (2011-2012-2013-2014) - Medtronic : devices (2011-2012-2013-2014) - Biotronik : devices (2011-2012-2013-2014) - Abbott Vascular : devices (2011-2012-2013-2014)
Rousseau Herve	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medtronic : STENT GRAFT (2011) - Bolton Medical : STENT GRAFT (2011) - Gore : STENT GRAFT (2011) - Gore : stent grafts (2012-2013-2014)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bolton Medical : stent grafts (2012-2013-2014)  C - Receipt of royalties for intellectual property. - Medtronic : stent grafts (2012-2013-2014)  D - Research funding (departmental or institutional). - Philips : RESARCH (2011) - Medtronic : stent grafts (2012-2013-2014)
Sechtem Udo	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulation (2011-2012)

## Guidelines on Aortic Disease 2014 (TF05) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Sechtem Udo	<ul style="list-style-type: none"> <li>- Novartis : Drugs (2011-2012)</li> <li>- Pfizer : Drugs (2011-2012-2013)</li> <li>- MSD SHARP &amp; DOHME GMBH : Drugs (2014)</li> <li>- Thera Technologies : Drugs (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Johnson &amp; Johnson : Stents (2011)</li> <li>- Novartis : Drugs (2011-2012)</li> <li>- Pfizer : Drugs (2012-2013-2014)</li> <li>- Astra Zeneca : Drugs (2013)</li> <li>- Boehringer-Ingelheim : Drugs (2013)</li> <li>- Siemens Healthcare : Drugs (2013)</li> <li>- Berlin Chemie AG : Drugs (2013)</li> <li>- Bayer Vital : Drugs (2013)</li> <li>- Bayer Healthcare : Drugs (2013-2014)</li> <li>- Daiichi Sankyo : Drugs (2014)</li> </ul>
Sirnes Per Anton	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Quintiles on behalf of Novartis : Investig fee CANTOS study (2012)</li> <li>- Merck Sharp &amp; Dohme : Investigator fee HPS2-THRIVE STUDY (2012)</li> <li>- Boehringer-Ingelheim : Investigator Fee Relyable study (2012)</li> <li>- Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)</li> <li>- GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012-2013)</li> <li>- SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012-2013)</li> <li>- NORMA on behalf of Janssen Cilar : Invest fee CANVAS study (2012-2013-2014)</li> </ul>

## Guidelines on Aortic Disease 2014 (TF05) - TF Members

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Sirnes Per Anton	<ul style="list-style-type: none"> <li>- Amgen : Speeker fee (2013)</li> <li>- Pfizer : speaker fee (2013)</li> <li>- Quintiles on behalf Garfield AF Registry : Fee Garfield AF registry (2013-2014)</li> <li>- Novartis : Investigatoprs fee CANTOS study (2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : investgator fee clinical studies hyperlipidemia, SCAD (THRIVE) (2011)</li> <li>- GlaxoSmithKline : investigator fee, clinical study , SCAD (2011)</li> <li>- Servier : investigator fee, clinical study, coronary artery disease (SIGNIFY) (2011)</li> <li>- Janssen-Cilag : investigator fee, clinical study, diabetes CVD (CANVAS) (2011)</li> </ul>
von Allmen Regula Sibylle	<p>None declared (2012-2013)</p> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- European Society of Vascular Surgery : Basic science: attenuation of ischaemia reperfusion injury (2014)</li> </ul>
Vrints Christian Jm	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : nterventional cardiology (2011)</li> <li>- Medtronic : Pacing - interventional cardiology (2011)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Bracco Pharmaceutical : contrast dye (2012)</li> <li>- Medtronic : Interventional cardiology devices (2012)</li> <li>- Medtronic : pacing, ICD &amp; stents (2013-2014)</li> </ul>

## Guidelines on Aortic Disease 2014 (TF05) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Antonini-Canterin Francesco	None declared (2012-2013-2014)
Back Magnus	None declared (2012-2014)  A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Cardiovascular (2013) - Resmed : Sleep Medicine (2013)  D - Research funding (departmental or institutional). - Evolva : Cardiovascular (2013)
Bakhutashvili Zviad	None declared (2012-2013-2014)
Bjornstad Knut	None declared (2012-2013-2014)
Cassar Andrew	None declared (2012-2013-2014)
Chammas Elie	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Sanofi Aventis : Irbesartan (2012) - GlaxoSmithKline : rosuvastatin, candesartan (2012)  - Servier : trimetazidine (2013-2014) - Novartis : valsartan (2013-2014)
Cikes Maja	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astellas : Heart transplantation (2012-2013) - Pfizer : Hypertension (2012-2013) - Berlin Chemie AG : Hypertension (2012-2013) - Sanofi Aventis : Hypertension, ACS (2012-2013) - Bayer : Anticoagulation (2014) - Novartis : Heart transplant (2014) - Berlin Chemie AG : Ischaemic heart disease (2014)
Czerny Martin	None declared (2013-2014)

## Guidelines on Aortic Disease 2014 (TF05) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Czerny Martin	B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bolton Medical : TEVAR (2012)
Deanfield John Eric	None declared (2012-2013-2014)
Demirbag Recep	None declared (2012-2013-2014)
Di Mario Carlo	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biosensors : Biomatrix stent (2012-2013-2014)</li> <li>- Abbott Vascular : Xience stent (2012-2013-2014)</li> <li>- Boston Scientific : CTO recanalisation (2013-2014)</li> <li>- Asahi INTECC : CTO recanalisation (2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Ikaria : Cardiac remodelling (2012)</li> <li>- Daiichi Sankyo, Eli-Lilly : Prasugrel (2012-2013-2014)</li> <li>- Medtronic : Resolute (2012-2013-2014)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- St Jude Medical : Optical coherence tomography (2012-2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Medicines Company : Bivalirudine (2012-2013-2014)</li> <li>- Abbott Vascular : EXCEL Study (2013-2014)</li> <li>- St Jude Medical : Ilumien OCT (2013-2014)</li> <li>- Medtronic : RESOLUTE 3 Study (2013-2014)</li> </ul>
Georgiou Georgios P	None declared (2012-2013-2014)
Grimm Michael	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Vascutec : basic research in aortic aneurysm research (2012-2013-2014)</li> <li>- Biotronik : basic research in heart failure (2012-2013-2014)</li> <li>- Novomed : basic research in heart failure (2012-2013-2014)</li> </ul>



## Guidelines on Aortic Disease 2014 (TF05) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Jondeau Guillaume	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : heart failure (2012) - Novartis : heart failure (2012-2013-2014) - Servier : angina (2013-2014)
Jonkaitiene Regina	None declared (2012-2013-2014)
Kovask Sirje	None declared (2012-2013-2014)
Kravchenko Ivan	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - National M.Amosov Institute of Cardiovascular Surgery of the National Academy of Medical Sciences of Ukraine. : Salary of the chief researcher (2012-2013-2014)
Kusljugic Zumreta	None declared (2012-2013-2014)
Kyto Ville	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Bayer : NOAC (2012-2013-2014) - Boehringer-Ingelheim : NOAC (2012-2013-2014)
Lighezan Daniel Florin	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Roche Diagnostics : Acute Coronary Syndromes Diagnostics (2012) - Merck Sharp & Dohme : Cardiodiovascular Risk (2012) - Bristol Myers Squibb : Chronic Hepatits (2012) - Daiichi Sankyo : Hypertension (2012) - Boehringer-Ingelheim : Hypertension and Anticoagulation (2012) - Sanofi Aventis : Hypertension and Coronary Syndromes (2012) - Abbott : Hypertension and Dyslipidemia (2012) - Pfizer : Hypertension and Dyslipidemia (2012) - Krka Pharma : Hypertension and Dyslipidemia (2012) - Egis Pharma : Ischaemic Heart Disease (2012) - GlaxoSmithKline : Pulmonary Diseases (2012)

## Guidelines on Aortic Disease 2014 (TF05) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lighezan Daniel Florin	<ul style="list-style-type: none"> <li>- Astra Zeneca : Hypertension and Dyslipidemia and Acute Coronary Syndromes (2012-2013-2014)</li> <li>- Servier : Hypertension and heart Failure (2012-2013-2014)</li> <li>- Berlin Chemie AG : Hypertension (2012-2014)</li> <li>- Boehringer-Ingelheim : Anticoagulation (2013-2014)</li> <li>- Pfizer and BMS Alliance : Anticoagulation (2013-2014)</li> <li>- Bayer : Anticoagulation (2014)</li> <li>- Roche Diagnostics : Heart Failure (2014)</li> <li>- Abbott : Hypertension (2014)</li> <li>- Novartis : Hypertension and Heart Failure (2014)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Richter Gedeon : Hypertension and Dyslipidemia (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure (2014)</li> </ul>
Lunegova Olga	None declared (2012-2013-2014)
Madaric Juraj	None declared (2012-2013-2014)
Mahdhaoui Abdallah	None declared (2012-2013-2014)
Molgaard Henning	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Speaker Fees: Cardiac Amyloidosis (2012-2013-2014)</li> <li>- Astra Zeneca : Speaker fees: Syncope (2012-2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Pfizer : Thaos database on famililal amyloidosis (2012-2013-2014)</li> </ul>
Musayev Ogtay	None declared (2012-2013-2014)
Nihoyannopoulos Petros	<p>None declared (2012)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- GSK : Consultant for Imaging studies (2013-2014)</li> </ul>

## Guidelines on Aortic Disease 2014 (TF05) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Pasquet Agnes A	D - Research funding (departmental or institutional). - Catholic university of Leuven , 1200 Brussels : cardiology cardiac vakves disease (2012-2013-2014) E - Research funding (personal). - Catholic university of Leuven , 1200 Brussels : cardiology cardiac vakves disease (2012-2013-2014)
Pepi Mauro	None declared (2012-2013-2014)
Perunicic Jovan	None declared (2012-2013-2014)
Rubinshtein Ronen	D - Research funding (departmental or institutional). - Philips : Computed Tomography (2012-2013-2014)
Salvador Taboada Maria Jesus	None declared (2012-2013-2014)
Sousa Uva Miguel	None declared (2012-2013) A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca : Antiplatelet therapy (2014)
Stasek Josef	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medicines Company : Cangrelol (2012) - Bristol Myers Squibb : KAI-9803 (2012) - F. Hoffman La Roche Ltd : Dalcetrapid (2012-2013) - Sanofi Aventis : SAR236553/REGN727 (2013-2014) - Edwards Lifesciences : TAVI (2014) B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Medicines Company : Cangrelol (2012) - Bristol Myers Squibb : KAI-9803 (2012) - F. Hoffman La Roche Ltd : Dalcetrapid (2012-2013) - Sanofi Aventis : SAR236553/REGN727 (2013-2014)
Stradins Peteris	None declared (2012-2013-2014)
Temesvari Andras	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Actelion : PAH treatment (2012-2013-2014)

## Guidelines on Aortic Disease 2014 (TF05) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Aspirin, Rivaroxaban (2012)</li> <li>- Amgen : Darbopietin (2012)</li> <li>- Servier : Ivabradine, Phase II investigational products (2012)</li> <li>- Amgen : Darbopietine (2013)</li> <li>- Bayer : Aspirin, Acarbose (2013-2014)</li> <li>- Servier : Ivabradine (2013-2014)</li> <li>- Janssen Cilag : Rivaroxaban (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Ivabradine, Phase II investigational products (2012)</li> <li>- Servier : Ivabradine (2014)</li> <li>- Janssen-Cilag : Rivaroxaban (2014)</li> </ul>
Tsioufis Costas	None declared (2012-2013-2014)
Van Sambeek Marc R H M	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Speakers fee (2012-2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- W.L. Gore &amp; associates : Speakers fee (2012-2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : Unrestricted research funding (2012-2013)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Medtronic : Unrestricted research funding (2012-2013)</li> <li>- Abbott Vascular : Departmental research funding (2014)</li> </ul>
Vilacosta Isidro	None declared (2012-2013-2014)
Vlachopoulos Charalambos	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Statin (2012-2013)</li> <li>- Bayer : Testosterone (2012-2013)</li> </ul>

## Guidelines on Aortic Disease 2014 (TF05) - Document Reviewers

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Vlachopoulos Charalambos	<ul style="list-style-type: none"> <li>- Astra Zeneca : Saxagliptin (2013)</li> <li>- Servier : Perindopril (2013-2014)</li> <li>- Boehringer-Ingelheim : Dabigatran (2014)</li> <li>- Pfizer : Eliquis (2014)</li> </ul>
Von Kodolitsch Yskert	None declared (2012-2013-2014)
Widenka Kazimierz	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Medtronic : Minimally Invasive Cardiac Surgery (2012-2013-2014)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Daiichii : Atrial Fib (2013)</li> <li>- Merck Sharp &amp; Dohme : Lipid Lowering (2013)</li> <li>- Philips : 3D echo (2014)</li> <li>- MSD : CV risk factors (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- European Research FP7 : CV Imaging (2013)</li> <li>- Servier : Imaging in ISchemic patients (2013)</li> <li>- Siemens Healthcare : 3d echo software and free style echo (2014)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Springer : ESC Textbook of CV Imaging (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Clinical trial (2014)</li> <li>- Ikaria : Clinical trial (2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Achenbach Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Siemens Healthcare : CT (2012-2013)</li> <li>- Servier : Imaging (2012-2013)</li> <li>- Guerbet : Imaging (2012-2013)</li> <li>- Bayer : Anticoagulation (2013)</li> <li>- Behring : Anticoagulation (2013)</li> <li>- Astra Zeneca : Antiplatelet Therapy (2013)</li> <li>- Abbott : Coronary Intervention (2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Coronary Intervention (2013-2014)</li> <li>- Siemens Healthcare : Imaging (2013-2014)</li> </ul>
Baumgartner Helmut	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012-2013-2014)</li> <li>- Actelion : Bosentan and Macicentan for PAH treatment in congenital heart disease (2013-2014)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014)</li> <li>- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Actelion : Bosentan for PAH treatment in congenital heart disease (2012-2013-2014)</li> <li>- Edwards Lifesciences : transcatheter valve implantation (2012-2013-2014)</li> <li>- St. Jude Medical : Occluders for shunt closure (ASD, PFO, PDA, VSD) (2013-2014)</li> <li>- Abbott : transcather mitral valve repair (Mitraclip) (2013-2014)</li> <li>- Direct Flow Medical : transcatheter valve implantation (2013-2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bax Jeroen	<p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Farma (2012-2013-2014)</li> <li>- Edwards Lifesciences : Heart Valves (2012-2013-2014)</li> <li>- GE Healthcare : Imaging (2012-2013-2014)</li> <li>- Lantheus Inc : Imaging (2012-2013-2014)</li> <li>- Boston Scientific : Pacing (2012-2013-2014)</li> <li>- Medtronic : Pacing (2012-2013-2014)</li> <li>- St Jude Medical : Pacing (2012-2013-2014)</li> <li>- Biotronik : Pacing (2012-2013-2014)</li> </ul>
Bueno Hector	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Novartis : Heart Failure and elinogrel (2012)</li> <li>- Bayer Healthcare : Aspirin, rivaroxaban (2012-2013-2014)</li> <li>- Roche Pharma : Dalcetrapib (2012-2013-2014)</li> <li>- Daiichi Sankyo : Prasugrel (2012-2013-2014)</li> <li>- Eli Lilly : Prasugrel (2012-2013-2014)</li> <li>- Astra Zeneca : Ticagrelor (2012-2013-2014)</li> <li>- BMS/Pfizer : Apixaban (2013)</li> <li>- Novartis : Relaxin (2013)</li> <li>- Sanofi Aventis : Clopidogrel (2013-2014)</li> <li>- Pfizer : Apixaban (2014)</li> <li>- Bristol Myers Squibb : Apixaban (2014)</li> <li>- Menarini : Ranolazine (2014)</li> <li>- Novartis : Serelaxin (2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Bueno Hector	E - Research funding (personal). - Astra Zeneca : Ticagrelor (2012-2013-2014)
Deaton M Christi	None declared (2013-2014)  D - Research funding (departmental or institutional). - Novo-Nordisk : patients with heart failure and diabetes (2012)
Erol Cetin	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Hypertension (2013-2014)  B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Servier : Perindopril (2012) - Menarini : Trandolapril (2012) - Menarini : Hypertension (2013-2014)  C - Receipt of royalties for intellectual property. - Astra Zeneca : Ticagrelor (2012)
Fagard Robert	None declared (2012-2013-2014)
Ferrari Roberto	A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Boehringer-Ingelheim : Anticoagulant and diabetes. Dagabitran (2012) - Medical Trials Analysis : Consultant in Clinical Trials (2012) - Servier : Myocardial ischemia and heart failure. Perindopril, ivabradine, amlodipine, trimetazidine (2012) - Novartis : Acute heart failure. Saralaxine (2013-2014) - Boehringer-Ingelheim : Anticoagulants and diabetes. Dagabitran (2013-2014) - Medical Trials Analysis : Consultant in clinical trials - expertise (2013-2014) - Merk Serono : Coronary artery disease, heart failure, beta blockers (2013-2014) - Servier : Myocardial ischemia and heart failure. Perindopril, Ivabradine, Amlodipine, Trimetazidine (2013-2014)  D - Research funding (departmental or institutional). - Fondazione Salvatore Maugeri : General (2012) - Schering-Plough : Anti-platelet agent TRACER (2012-2013-2014)



## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Ferrari Roberto	<ul style="list-style-type: none"> <li>- Servier : Perindopril, ivabradine, amlodipine CLARifY and SIGNifY (2012-2013-2014)</li> </ul>
Hasdai David	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Pradaxa (2012-2013-2014)</li> <li>- Bayer : Rivaroxiban (2012-2013-2014)</li> <li>- Astra Zeneca : Ticagrelor (2012-2013-2014)</li> </ul>
Hoes Arno	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : Member Scientific Committee of Zorro; a research program sponsored by an unrestricted grant from Boehringer-Ingelheim with the aim to improve anticoagulant care in the Netherlands (2012)</li> <li>- Various : I chair a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)</li> <li>- Zorg binnen Bereik : Member of project team of Zorg Binnen Bereik, a Dutch Achmea (health insurance company) and Philips sponsored research program to test patient e-health platforms in patients with chronic disease (heart failure, COPD and diabetes) (2012-2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- I am the director of a large (around 500 employees) research and teaching institute within our University Medical Center. We perform both investigator- and industry-driven research projects with a number of pharmaceutical and diagnostic companies. In addition, some of my members of staff receive unrestricted grants for research projects from a number of companies. It is our explicit policy to work with several companies and not to focus on one or two industrial partners. I receive no personal payment from any industrial partner. (2012-2013-2014)</li> </ul>
Kirchhof Paulus	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boehringer-Ingelheim : cardiovascular (2012-2013-2014)</li> <li>- Daiichi Sankyo : cardiovascular (2012-2013-2014)</li> <li>- Medtronic : cardiovascular (2012-2013-2014)</li> <li>- Pfizer : cardiovascular (2012-2013-2014)</li> <li>- St Jude Medical : cardiovascular (2012-2013-2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- Sanofi Aventis : cardiovascular (2012-2013-2014)</li> <li>- Meda pharma : cardiovascular (2012-2013-2014)</li> <li>- Bristol Myers Squibb : cardiovascular (2012-2013-2014)</li> <li>- Merck Sharp &amp; Dohme : cardiovascular (2012-2013-2014)</li> <li>- Otsuka Pharmaceuticals Development and Commercialization (consultancy) : cardiovascular (2012-2013-2014)</li> <li>- Johnson &amp; Johnson : cardiovascular (2014)</li> <li>- Bayer Healthcare : cardiovascular (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Portola Pharmaceuticals : cardiovascular (2012)</li> <li>- Boehringer-Ingelheim : cardiovascular (2012-2013-2014)</li> <li>- Bayer Healthcare : cardiovascular (2012-2013-2014)</li> <li>- BMS / Pfizer alliance : cardiovascular (2012-2013-2014)</li> <li>- Gilead : cardiovascular (2013)</li> <li>- Daiichi Sankyo : cardiovascular (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : cardiovascular (2012-2013)</li> <li>- Sanofi Aventis : cardiovascular (2012-2013)</li> <li>- Meda pharma : cardiovascular (2012-2013-2014)</li> <li>- British Heart Foundation : cardiovascular (2014)</li> <li>- European Union (FP7) : cardiovascular (2014)</li> <li>- Daiichi Sankyo : cardiovascular (IIT grant to AFNET) (2014)</li> <li>- St Jude Medical : cardiovascular (IIT grant to AFNET) (2014)</li> <li>- Sanofi Aventis : cardiovascular (IIT grant to AFNET) (2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Kirchhof Paulus	<ul style="list-style-type: none"> <li>- BMS/Pfizer : cardiovascular (IIT grant to AFNET) (2014)</li> <li>- Fondation Leducq : cardiovascular (starting in October 2014) (2014)</li> <li>- German Ministry of Education and Research (BMBF) : cardiovascular (to AFNET) (2014)</li> </ul>
Knuuti Juhani	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Lantheus Inc : Perfusion imaging tracer development (2012-2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Servier : Vascular inflammation (2012-2013-2014)</li> <li>- Athera : vascular inflammation (2012-2013-2014)</li> <li>- Orion Pharma : Heart failure drug research (2014)</li> </ul>
Kolh Philippe H	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Regado Biosciences : Antithrombotic agents (2012)</li> <li>- Astra Zeneca : Antiplatelet agents (2012-2013-2014)</li> <li>- B.Braun : Surgical instruments (2013-2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Merck Sharp &amp; Dohme : Antistaphylococcic vaccine (2012)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- St Jude Medical : Cardiac valves (2012-2013)</li> <li>- Boston Scientific : Coronary stents (2012-2013)</li> <li>- Siemens Healthcare : Medical imaging (2012-2013)</li> <li>- Johnson &amp; Johnson : Thoracoscopic devices (2012-2013)</li> <li>- Edwards Lifesciences : Cardiac valves (2012-2013-2014)</li> <li>- Medtronic : Cardiac valves (2012-2013-2014)</li> </ul>
Lancellotti Patrizio	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Boston Scientific : Heart Failure (2012)</li> <li>- Servier : Heart Failure (2013)</li> <li>- Abbott : MitraClip (2013)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Lancellotti Patrizio	<ul style="list-style-type: none"> <li>- Menarini : nebivolol (2014)</li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Astra Zeneca : Brilique (2012)</li> <li>- Servier : Coversyl (2012)</li> <li>- Abbott Vascular : MitraClip (2012)</li> <li>- Astrazeneca : Dyslipidemia (2013)</li> <li>- Boston Scientific : CRT (2014)</li> <li>- Servier : procoralan (2014)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Actelion : Pulmonary Hypertension (2013)</li> </ul> </li> </ul>
Linhart Ales	<ul style="list-style-type: none"> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Servier : Arterial hypertension (2012-2013-2014)</li> <li>- Boehringer-Ingelheim : Arterial hypertension, atrial fibrillation (2012-2013-2014)</li> <li>- GlaxoSmithKline : Atherosclerosis (2012-2013-2014)</li> <li>- Merck Sharp &amp; Dohme : Dyslipidemia (2012-2013-2014)</li> <li>- Bayer Schering Pharma : Dyslipidemia, pulmonary hypertension, atrial fibrillation (2012-2013-2014)</li> <li>- Shire HGT : Fabry disease (2012-2013-2014)</li> <li>- Genzyme : Fabry disease (2012-2013-2014)</li> <li>- Actelion : Pulmonary hypertension (2012-2013-2014)</li> </ul> </li> <li>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- Shire HGT : Fabry disease (2012)</li> </ul> </li> <li>D - Research funding (departmental or institutional).               <ul style="list-style-type: none"> <li>- Shire HGT : Fabry disease (2014)</li> </ul> </li> </ul>
Nihoyannopoulos Petros	<ul style="list-style-type: none"> <li>None declared (2012)</li> <li>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.               <ul style="list-style-type: none"> <li>- GSK : Consultant for Imaging studies (2013-2014)</li> </ul> </li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Piepoli Massimo Francesco	<p>None declared (2013-2014)</p> <p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Chiesi Pharma : Anti-dyslipidemic therapy (2012)</p>
Ponikowski Piotr	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Amgen : heart failure (2012)</li> <li>- Cothera : heart failure (2012)</li> <li>- Coridea : heart failure (2012)</li> <li>- Boehringer-Ingelheim : anticoagulant (2012-2013-2014)</li> <li>- Bristol Myers Squibb : anticoagulant (2012-2013-2014)</li> <li>- Respicardia : anticoagulant (2012-2013-2014)</li> <li>- Abbott Vascular : devices (2012-2013-2014)</li> <li>- Novartis : heart failure (2012-2013-2014)</li> <li>- Johnson &amp; Johnson : heart failure (2012-2013-2014)</li> <li>- Bayer Healthcare : heart failure (2012-2013-2014)</li> <li>- Vifor Pharma ltd : heart failure (2012-2013-2014)</li> <li>- Pfizer : heart failure, anticoagulant (2012-2013-2014)</li> <li>- Servier : heart failure, coronary artery disease (2012-2013-2014)</li> <li>- Bayer : anticoagulant (2013-2014)</li> <li>- ROSCHE : diabetes (2013-2014)</li> <li>- Cardioentis : heart failure (2013-2014)</li> <li>- CIBIEM : heart failure (2013-2014)</li> <li>- Amgen : heart failure, lipids (2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional). - Vifor Pharma ltd : heart failure (2012-2013-2014)</p>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Sirnes Per Anton	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Quintiles on behalf of Novartis : Investig fee CANTOS study (2012)</li> <li>- Merck Sharp &amp; Dohme : Investigator fee HPS2-THRIVE STUDY (2012)</li> <li>- Boehringer-Ingelheim : Investigator Fee Reliable study (2012)</li> <li>- Schering-Plough : Investigator fee TRA2P-TIMI50 study (2012)</li> <li>- GlaxoSmithKline : Investig fee HZC113108 and LPL100601 studies (2012-2013)</li> <li>- SticaresInterACt on behalf of Servier : Investig Fee SIGNIFY study (2012-2013)</li> <li>- NORMA on behalf of Janssen Cilar : Invest fee CANVAS study (2012-2013-2014)</li> <li>- Amgen : Speeker fee (2013)</li> <li>- Pfizer : speeker fee (2013)</li> <li>- Quintiles on behalf Garfield AF Registry : Fee Garfield AF registry (2013-2014)</li> <li>- Novartis : Investigatoprs fee CANTOS study (2013-2014)</li> </ul>
Tamargo Juan Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- sanodi-aventis : Dronedarone-antiarrhythmic agent (2012)</li> <li>- Menarini : Ranolazina (2013)</li> <li>- Menarini : Ranolazine (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Astra Zeneca (Unrestricted Grant) : Candesartan, Felodipine, Atenolol (2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Unrestricted Grant (2013)</li> </ul> <p>E - Research funding (personal).</p> <ul style="list-style-type: none"> <li>- Astra -Zeneca Foundation (NON-PROFIT FOUNDATION). two years Unrestricted Grant : None (2012)</li> <li>- Instituto de Salud Carlos III. Ministerio de Economía y Competitividad. Gobierno de España : No product/device (2014)</li> </ul>
Tendera Michal	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Bayer : Aspirin, Rivaroxaban (2012)</li> <li>- Amgen : Darbopietin (2012)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Tendera Michal	<ul style="list-style-type: none"> <li>- Servier : Ivabradine, Phase II investigational products (2012)</li> <li>- Amgen : Darbopoietine (2013)</li> <li>- Bayer : Aspirin, Acarbose (2013-2014)</li> <li>- Servier : Ivabradine (2013-2014)</li> <li>- Janssen Cilag : Rivaroxaban (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Servier : Ivabradine, Phase II investigational products (2012)</li> <li>- Servier : Ivabradine (2014)</li> <li>- Janssen-Cilag : Rivaroxaban (2014)</li> </ul>
Torbicki Adam	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Cardiomems : implanted pulmonary artery pressure sensor (2012)</li> <li>- United Therapeutics : Pulmonary arterial hypertension (2012)</li> <li>- Lilly : pulmonary arterial hypertension - tadalafil (2012)</li> <li>- AOP Orphan Pharmaceuticals : Pulmonary arterial hypertension - treprostinil (2012)</li> <li>- Bristol Myers Squibb : thromboembolic disease - Apixaban (2012)</li> <li>- GlaxoSmithKline : pulmonary arterial hypertension - ambrisentan (2012-2013)</li> <li>- Actelion : pulmonary arterial hypertension - macitentan, selexipag (2012-2013-2014)</li> <li>- Bayer Healthcare : pulmonary arterial hypertension - iloprost, riociguat, VTE - xarelto (2012-2013-2014)</li> <li>- Bristol Myers Squibb : Pulmonary arterial hypertension (2013)</li> <li>- Lilly : pulmonary arterial hypertension - ambrisentan (2013)</li> <li>- Novartis : pulmonary hypertension (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Sanofi Aventis : Thromboembolic disease (2012)</li> <li>- Bayer Healthcare : Pulmonary hypertension (2012-2013-2014)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Wijns William	<p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Tryton : device (2012)</li> <li>- Astra Zeneca : pharma (2012)</li> <li>- Biosensors : device (2012-2013-2014)</li> <li>- Boston Scientific : device (2012-2013-2014)</li> <li>- Edwards Lifesciences : device (2012-2013-2014)</li> <li>- Medtronic : device (2012-2013-2014)</li> <li>- St Jude Medical : device (2012-2013-2014)</li> <li>- Biotronik : device (2012-2013-2014)</li> <li>- Terumo Inc : device (2012-2013-2014)</li> <li>- Abbott Vascular : device (2012-2013-2014)</li> <li>- Cordis : device (2012-2013-2014)</li> <li>- Orbus Nech : device (2012-2013-2014)</li> <li>- MICELL : device (2012-2013-2014)</li> <li>- Vessix : device (2012-2013-2014)</li> <li>- GlaxoSmithKline : drug (2012-2013-2014)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Cardio3 Biosciences : cell therapy (2012-2013-2014)</li> <li>- Boston Scientific : device (2012-2013-2014)</li> <li>- Medtronic : device (2012-2013-2014)</li> <li>- St Jude Medical : device (2012-2013-2014)</li> <li>- Biotronik : device (2012-2013-2014)</li> <li>- Abbott Laboratories : device (2012-2013-2014)</li> </ul>



## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Wijns William	<ul style="list-style-type: none"> <li>- MICELL : device (2012-2013-2014)</li> <li>- Therabel : drug (2012-2013-2014)</li> </ul>
Windecker Stephan	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Biosensors : Stent (2012)</li> <li>- Boston Scientific : Stent (2012)</li> <li>- Cordis : Stent (2012)</li> <li>- Edwards Lifesciences : TAVI (2012)</li> <li>- Astra Zeneca : Antiplatelet drug (2012-2013)</li> <li>- Eli Lilly : Antiplatelet drug (2012-2013)</li> <li>- Abbott : Stent (2012-2013)</li> <li>- Medtronic : Stent (2012-2013)</li> <li>- Biotronik : Stent (2012-2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Abbott : Stent (2012)</li> <li>- Biosensors : Stent (2012)</li> <li>- Medtronic : Stent (2012)</li> <li>- Cordis : Stent (2012)</li> <li>- St Jude Medical : OCT (2012-2013-2014)</li> <li>- Biotronik : Stent (2012-2013-2014)</li> </ul>
Zamorano Gomez Jose Luis	<p>A - Direct Personal payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- Abbott Vascular : Help in Design Echocardiographic protocol (2012)</li> <li>- Merck Sharp &amp; Dohme : Lecture (2012)</li> <li>- Daiichii : Atrial Fib (2013)</li> <li>- Merck Sharp &amp; Dohme : Lipid Lowering (2013)</li> </ul>

## Committee for Practice Guidelines 2012-2014

For ESC Guidelines: The report below lists declarations of interest as reported to the ESC by the experts covering the period of the Guidelines production, from Task Force creation to publication.

Expert	Type of Relationship with Industry
Zamorano Gomez Jose Luis	<ul style="list-style-type: none"> <li>- Philips : 3D echo (2014)</li> <li>- MSD : CV risk factors (2014)</li> <li>- Toshiba medical imaging : fusion imaging 3D echo CT (2014)</li> </ul> <p>B - Payment to your Institution: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc.</p> <ul style="list-style-type: none"> <li>- European Research Foundation FP7 : CV Imaging (2012)</li> <li>- European Research FP7 : CV Imaging (2013)</li> <li>- Servier : Imaging in ISchemic patients (2013)</li> <li>- Siemens Healthcare : 3d echo software and free style echo (2014)</li> </ul> <p>C - Receipt of royalties for intellectual property.</p> <ul style="list-style-type: none"> <li>- Springer : ESC Textbook of CV Imaging (2012-2013)</li> </ul> <p>D - Research funding (departmental or institutional).</p> <ul style="list-style-type: none"> <li>- Astra Zeneca : Clinical trial (2014)</li> <li>- Icaria : Clinical trial (2014)</li> </ul>